ANA598
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ANA598, covering 2012-11-14 to 2017-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection [Phase 2]